Muscarinic receptor antagonist therapy improves acute pulmonary dysfunction after smoke inhalation injury in sheep. 2010

Collette Jonkam, and Yong Zhu, and Sam Jacob, and Sebastian Rehberg, and Edward Kraft, and Atsumori Hamahata, and Yoshimitsu Nakano, and Lillian D Traber, and David N Herndon, and Daniel L Traber, and Hal K Hawkins, and Perenlei Enkhbaatar, and Robert A Cox
Shriners Hospitals for Children and the University of Texas Medical Branch, Galveston, TX, USA.

OBJECTIVE Inhalation injury contributes to the morbidity and mortality of burn victims. In humans and in an ovine model of combined smoke inhalation and burn injury, bronchospasm and acute airway obstruction contribute to progressive pulmonary insufficiency. This study tests the hypothesis that muscarinic receptor antagonist therapy with tiotropium bromide, an M1 and M3 muscarinic receptor antagonist, will decrease the airway constrictive response and acute bronchial obstruction to improve pulmonary function compared to injured animals without treatment. METHODS Randomized, prospective study involving 32 sheep. METHODS Large-animal intensive care research laboratory. METHODS The study consisted of six groups: a sham group (n=4, instrumented noninjured), a control group (n=6, injured and not treated), and tiotropium bromide-treated groups, including both preinjury and postinjury nebulization protocols. Treatments for these groups included nebulization with 36 μg of tiotropium bromide 1 hr before injury (n=6) and postinjury nebulization protocols of 18 μg (n=6), 36 μg (n=6), and 72 μg (n=4) administered 1 hr after injury. All treated groups received an additional 14.4 μg every 4 hrs for the 24-hr study period. RESULTS Pretreatment with tiotropium bromide significantly attenuated the increases in ventilatory pressures, pulmonary dysfunction, and upper airway obstruction that occur after combined smoke inhalation and burn injury. Postinjury treatments with tiotropium bromide were as effective as pretreatment in preventing pulmonary insufficiency, although a trend toward decreased obstruction was present only in all post-treatment conditions. There was no improvement noted in pulmonary function in animals that received a higher dose of tiotropium bromide. CONCLUSIONS This study describes a contribution of acetylcholine to the airway constrictive and lumenal obstructive response after inhalation injury and identifies low-dose nebulization of tiotropium bromide as a potentially efficacious therapy for burn patients with severe inhalation injury.

UI MeSH Term Description Entries
D011659 Pulmonary Gas Exchange The exchange of OXYGEN and CARBON DIOXIDE between alveolar air and pulmonary capillary blood that occurs across the BLOOD-AIR BARRIER. Exchange, Pulmonary Gas,Gas Exchange, Pulmonary
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D012128 Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA. ARDS, Human,Acute Respiratory Distress Syndrome,Adult Respiratory Distress Syndrome,Pediatric Respiratory Distress Syndrome,Respiratory Distress Syndrome, Acute,Respiratory Distress Syndrome, Adult,Respiratory Distress Syndrome, Pediatric,Shock Lung,Distress Syndrome, Respiratory,Distress Syndromes, Respiratory,Human ARDS,Lung, Shock,Respiratory Distress Syndromes,Syndrome, Respiratory Distress
D012129 Respiratory Function Tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Lung Function Tests,Pulmonary Function Tests,Function Test, Pulmonary,Function Tests, Pulmonary,Pulmonary Function Test,Test, Pulmonary Function,Tests, Pulmonary Function,Function Test, Lung,Function Test, Respiratory,Function Tests, Lung,Function Tests, Respiratory,Lung Function Test,Respiratory Function Test,Test, Lung Function,Test, Respiratory Function,Tests, Lung Function,Tests, Respiratory Function
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000069447 Tiotropium Bromide A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide,BA 679 BR,BA-679 BR,Spiriva,Tiotropium,679 BR, BA,BA679 BR,BR, BA 679,Bromide, Tiotropium
D000402 Airway Obstruction Any hindrance to the passage of air into and out of the lungs. Choking,Airway Obstructions,Obstruction, Airway,Obstructions, Airway

Related Publications

Collette Jonkam, and Yong Zhu, and Sam Jacob, and Sebastian Rehberg, and Edward Kraft, and Atsumori Hamahata, and Yoshimitsu Nakano, and Lillian D Traber, and David N Herndon, and Daniel L Traber, and Hal K Hawkins, and Perenlei Enkhbaatar, and Robert A Cox
December 1988, The American journal of pathology,
Collette Jonkam, and Yong Zhu, and Sam Jacob, and Sebastian Rehberg, and Edward Kraft, and Atsumori Hamahata, and Yoshimitsu Nakano, and Lillian D Traber, and David N Herndon, and Daniel L Traber, and Hal K Hawkins, and Perenlei Enkhbaatar, and Robert A Cox
October 2007, Shock (Augusta, Ga.),
Collette Jonkam, and Yong Zhu, and Sam Jacob, and Sebastian Rehberg, and Edward Kraft, and Atsumori Hamahata, and Yoshimitsu Nakano, and Lillian D Traber, and David N Herndon, and Daniel L Traber, and Hal K Hawkins, and Perenlei Enkhbaatar, and Robert A Cox
February 2008, Clinical science (London, England : 1979),
Collette Jonkam, and Yong Zhu, and Sam Jacob, and Sebastian Rehberg, and Edward Kraft, and Atsumori Hamahata, and Yoshimitsu Nakano, and Lillian D Traber, and David N Herndon, and Daniel L Traber, and Hal K Hawkins, and Perenlei Enkhbaatar, and Robert A Cox
March 2005, Clinical science (London, England : 1979),
Collette Jonkam, and Yong Zhu, and Sam Jacob, and Sebastian Rehberg, and Edward Kraft, and Atsumori Hamahata, and Yoshimitsu Nakano, and Lillian D Traber, and David N Herndon, and Daniel L Traber, and Hal K Hawkins, and Perenlei Enkhbaatar, and Robert A Cox
November 1991, Critical care medicine,
Collette Jonkam, and Yong Zhu, and Sam Jacob, and Sebastian Rehberg, and Edward Kraft, and Atsumori Hamahata, and Yoshimitsu Nakano, and Lillian D Traber, and David N Herndon, and Daniel L Traber, and Hal K Hawkins, and Perenlei Enkhbaatar, and Robert A Cox
September 1989, The Journal of trauma,
Collette Jonkam, and Yong Zhu, and Sam Jacob, and Sebastian Rehberg, and Edward Kraft, and Atsumori Hamahata, and Yoshimitsu Nakano, and Lillian D Traber, and David N Herndon, and Daniel L Traber, and Hal K Hawkins, and Perenlei Enkhbaatar, and Robert A Cox
November 2012, Shock (Augusta, Ga.),
Collette Jonkam, and Yong Zhu, and Sam Jacob, and Sebastian Rehberg, and Edward Kraft, and Atsumori Hamahata, and Yoshimitsu Nakano, and Lillian D Traber, and David N Herndon, and Daniel L Traber, and Hal K Hawkins, and Perenlei Enkhbaatar, and Robert A Cox
January 1992, Lung,
Collette Jonkam, and Yong Zhu, and Sam Jacob, and Sebastian Rehberg, and Edward Kraft, and Atsumori Hamahata, and Yoshimitsu Nakano, and Lillian D Traber, and David N Herndon, and Daniel L Traber, and Hal K Hawkins, and Perenlei Enkhbaatar, and Robert A Cox
December 2007, Critical care medicine,
Collette Jonkam, and Yong Zhu, and Sam Jacob, and Sebastian Rehberg, and Edward Kraft, and Atsumori Hamahata, and Yoshimitsu Nakano, and Lillian D Traber, and David N Herndon, and Daniel L Traber, and Hal K Hawkins, and Perenlei Enkhbaatar, and Robert A Cox
September 2005, Shock (Augusta, Ga.),
Copied contents to your clipboard!